Lupin Manufacturing Solutions: Empagliflozin API gets CADIFA approval from ANVISA, Brazil
Advertisement
Lupin Manufacturing Solutions has announced that Empagliflozin API, manufactured at its Vizag facility, has received CADIFA approval from ANVISA, Brazil.
Empagliflozin is a proven SGLT-2 inhibitor used in type-2 diabetes care, helping patients control blood sugar and reduce long term complications.
"This approval marks more than a regulatory success; it is a stride toward expanding access to high-quality, effective diabetes therapies worldwide. Backed by scientific rigor, GMP-compliant manufacturing, and a commitment to regulatory excellence, our Empagliflozin API strengthens the fight against type 2 diabetes. Because when it comes to global health, science knows no boundaries," the company stated in a LinkedIn Post.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.